gamma-aminobutyric acid has been researched along with Anasarca in 26 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We assessed the efficacy and safety of a flexible-dose pregabalin regimen in patients with diabetic peripheral neuropathy (DPN) or postherpetic neuralgia (PHN) under clinical practice conditions." | 9.13 | Efficacy and safety of pregabalin in patients with diabetic peripheral neuropathy or postherpetic neuralgia: Open-label, non-comparative, flexible-dose study. ( Baron, R; Binder, A; Brasser, M; Brunnmüller, U; May, M, 2008) |
| "To evaluate the efficacy and safety of pregabalin in the treatment of postherpetic neuralgia (PHN)." | 9.10 | Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. ( Bockbrader, H; Corbin, AE; Dworkin, RH; Garofalo, EA; LaMoreaux, L; Poole, RM; Sharma, U; Young, JP, 2003) |
| "The results of this review will assist physicians to better appreciate pregabalin's risk for edema or congestive heart failure and will be pertinent to the thousands of patients worldwide who are administered this medication." | 8.89 | Risk of heart failure and edema associated with the use of pregabalin: a systematic review. ( Chen, M; Ho, JM; Juurlink, DN; Perrier, L; Straus, SE; Tricco, AC, 2013) |
| "Gabapentin has been shown to be well tolerated and effective in the management of the pain associated with postherpetic neuralgia (PHN)." | 8.82 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| "In this pooled analysis of adverse-event data from 3 clinical trials in patients with PHN, the incidence of peripheral edema was increased when gabapentin was titrated to >or=1800 mg/d." | 8.82 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| "To report a case of paraplegia with limb edema caused by pregabalin." | 7.78 | Reversible post-pregabalin peripheral edema in a spinal cord injury patient. ( Duman, I; Guzelkucuk, U; Tan, AK; Yılmaz, B, 2012) |
| "Pregabalin, which is one of medications used for neuropathic pain, might cause limb edema, that is, a condition needs differential diagnosis." | 7.78 | Reversible post-pregabalin peripheral edema in a spinal cord injury patient. ( Duman, I; Guzelkucuk, U; Tan, AK; Yılmaz, B, 2012) |
| "We report two patients with refractory epilepsy who developed unilateral painful gynecomastia and lower extremity pain (one of them localized and the other one diffuse), shortly after receiving Pregabalin (PGB)." | 7.73 | Two cases of painful gynecomastia and lower extremity pain in association with pregabalin therapy. ( Málaga, I; Sanmarti, FX, 2006) |
| " When evaluated in the model of neuropathic pain caused by partial ligation of sciatic nerve, the hexanic extract inhibited the mechanical allodynia (77 +/- 7%), with a similar efficacy to the gabapentin (71 +/- 10%)." | 7.72 | Anti-allodynic and anti-oedematogenic properties of the extract and lignans from Phyllanthus amarus in models of persistent inflammatory and neuropathic pain. ( Calixto, JB; Kassuya, CA; Rehder, VL; Silvestre, AA, 2003) |
| "This study investigated the anti-allodynic and anti-oedematogenic effects of the hexanic extract, lignan-rich fraction and purified lignans from a plant used in the traditional medicine, Phyllanthus amarus, in the inflammatory and neuropathic models of nociception." | 7.72 | Anti-allodynic and anti-oedematogenic properties of the extract and lignans from Phyllanthus amarus in models of persistent inflammatory and neuropathic pain. ( Calixto, JB; Kassuya, CA; Rehder, VL; Silvestre, AA, 2003) |
| " The most frequently used dosing regimen involved a starting dose of 150mg/d and dose escalation to 300mg/d after one week (mean: 301mg/d, administered in two doses)." | 6.73 | Efficacy and safety of pregabalin in patients with diabetic peripheral neuropathy or postherpetic neuralgia: Open-label, non-comparative, flexible-dose study. ( Baron, R; Binder, A; Brasser, M; Brunnmüller, U; May, M, 2008) |
| " Given the maximal dosage studied, pregabalin had acceptable tolerability compared to placebo despite a greater incidence of side effects, which were generally mild to moderate in intensity." | 6.71 | Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. ( Bockbrader, H; Corbin, AE; Dworkin, RH; Garofalo, EA; LaMoreaux, L; Poole, RM; Sharma, U; Young, JP, 2003) |
| "The aim of this study was to assess the dose dependence of adverse events with gabapentin by determining the relationship between increasing doses of gabapentin and the onset and/or worsening of adverse events in patients with PHN." | 6.42 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| " Dizziness and somnolence, the other most commonly occurring adverse events, were transient and did not occur more frequently or worsen with titration to >or=1800 mg/d." | 6.42 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| " The 3 most common adverse events were dizziness, somnolence, and peripheral edema." | 6.42 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| " The analysis of adverse events was based on 3 distinct groups: patients who received gabapentin <1800 mg/d, those who received gabapentin >or=1800 mg/d, and those who received placebo." | 6.42 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| " It is assumed that adverse events occurring with gabapentin are dose related, their frequency and severity increasing with increasing doses." | 6.42 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| "Gabapentin has been shown to be well tolerated and effective in the management of the pain associated with postherpetic neuralgia (PHN)." | 6.42 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| "Gabapentin was initiated at 300 mg/d and titrated to maintenance doses of 1800 to 3600 mg/d by day 12 to 24." | 6.42 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| "The edema was considered to be caused by pregabalin and the medicine was ceased gradually." | 5.38 | Reversible post-pregabalin peripheral edema in a spinal cord injury patient. ( Duman, I; Guzelkucuk, U; Tan, AK; Yılmaz, B, 2012) |
| "We assessed the efficacy and safety of a flexible-dose pregabalin regimen in patients with diabetic peripheral neuropathy (DPN) or postherpetic neuralgia (PHN) under clinical practice conditions." | 5.13 | Efficacy and safety of pregabalin in patients with diabetic peripheral neuropathy or postherpetic neuralgia: Open-label, non-comparative, flexible-dose study. ( Baron, R; Binder, A; Brasser, M; Brunnmüller, U; May, M, 2008) |
| "To evaluate the efficacy and safety of pregabalin in the treatment of postherpetic neuralgia (PHN)." | 5.10 | Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. ( Bockbrader, H; Corbin, AE; Dworkin, RH; Garofalo, EA; LaMoreaux, L; Poole, RM; Sharma, U; Young, JP, 2003) |
| "The results of this review will assist physicians to better appreciate pregabalin's risk for edema or congestive heart failure and will be pertinent to the thousands of patients worldwide who are administered this medication." | 4.89 | Risk of heart failure and edema associated with the use of pregabalin: a systematic review. ( Chen, M; Ho, JM; Juurlink, DN; Perrier, L; Straus, SE; Tricco, AC, 2013) |
| "Gabapentin has been shown to be well tolerated and effective in the management of the pain associated with postherpetic neuralgia (PHN)." | 4.82 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| "In this pooled analysis of adverse-event data from 3 clinical trials in patients with PHN, the incidence of peripheral edema was increased when gabapentin was titrated to >or=1800 mg/d." | 4.82 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| "To report a case of paraplegia with limb edema caused by pregabalin." | 3.78 | Reversible post-pregabalin peripheral edema in a spinal cord injury patient. ( Duman, I; Guzelkucuk, U; Tan, AK; Yılmaz, B, 2012) |
| "Pregabalin, which is one of medications used for neuropathic pain, might cause limb edema, that is, a condition needs differential diagnosis." | 3.78 | Reversible post-pregabalin peripheral edema in a spinal cord injury patient. ( Duman, I; Guzelkucuk, U; Tan, AK; Yılmaz, B, 2012) |
| "We report two patients with refractory epilepsy who developed unilateral painful gynecomastia and lower extremity pain (one of them localized and the other one diffuse), shortly after receiving Pregabalin (PGB)." | 3.73 | Two cases of painful gynecomastia and lower extremity pain in association with pregabalin therapy. ( Málaga, I; Sanmarti, FX, 2006) |
| "This study investigated the anti-allodynic and anti-oedematogenic effects of the hexanic extract, lignan-rich fraction and purified lignans from a plant used in the traditional medicine, Phyllanthus amarus, in the inflammatory and neuropathic models of nociception." | 3.72 | Anti-allodynic and anti-oedematogenic properties of the extract and lignans from Phyllanthus amarus in models of persistent inflammatory and neuropathic pain. ( Calixto, JB; Kassuya, CA; Rehder, VL; Silvestre, AA, 2003) |
| " When evaluated in the model of neuropathic pain caused by partial ligation of sciatic nerve, the hexanic extract inhibited the mechanical allodynia (77 +/- 7%), with a similar efficacy to the gabapentin (71 +/- 10%)." | 3.72 | Anti-allodynic and anti-oedematogenic properties of the extract and lignans from Phyllanthus amarus in models of persistent inflammatory and neuropathic pain. ( Calixto, JB; Kassuya, CA; Rehder, VL; Silvestre, AA, 2003) |
| " The most frequently used dosing regimen involved a starting dose of 150mg/d and dose escalation to 300mg/d after one week (mean: 301mg/d, administered in two doses)." | 2.73 | Efficacy and safety of pregabalin in patients with diabetic peripheral neuropathy or postherpetic neuralgia: Open-label, non-comparative, flexible-dose study. ( Baron, R; Binder, A; Brasser, M; Brunnmüller, U; May, M, 2008) |
| " Given the maximal dosage studied, pregabalin had acceptable tolerability compared to placebo despite a greater incidence of side effects, which were generally mild to moderate in intensity." | 2.71 | Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. ( Bockbrader, H; Corbin, AE; Dworkin, RH; Garofalo, EA; LaMoreaux, L; Poole, RM; Sharma, U; Young, JP, 2003) |
| "The aim of this study was to assess the dose dependence of adverse events with gabapentin by determining the relationship between increasing doses of gabapentin and the onset and/or worsening of adverse events in patients with PHN." | 2.42 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| "Gabapentin has been shown to be well tolerated and effective in the management of the pain associated with postherpetic neuralgia (PHN)." | 2.42 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| " The analysis of adverse events was based on 3 distinct groups: patients who received gabapentin <1800 mg/d, those who received gabapentin >or=1800 mg/d, and those who received placebo." | 2.42 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| " The 3 most common adverse events were dizziness, somnolence, and peripheral edema." | 2.42 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| " Dizziness and somnolence, the other most commonly occurring adverse events, were transient and did not occur more frequently or worsen with titration to >or=1800 mg/d." | 2.42 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| "Gabapentin was initiated at 300 mg/d and titrated to maintenance doses of 1800 to 3600 mg/d by day 12 to 24." | 2.42 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| " It is assumed that adverse events occurring with gabapentin are dose related, their frequency and severity increasing with increasing doses." | 2.42 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| "Outcome measures were postsurgical pain at rest and during walking, consumption of opioids for pain rescue, knee swelling and knee range of motion, and complications." | 1.46 | Methylprednisolone reduces pain and decreases knee swelling in the first 24 h after fast-track unicompartmental knee arthroplasty. ( Hansen, TB; Munk, S; Rytter, S; Stilling, M, 2017) |
| "Gabapentin (GBP) is an anti-convulsive drug often used as analgesic to control neuropathic pain." | 1.39 | Oral gabapentin treatment accentuates nerve and peripheral inflammatory responses following experimental nerve constriction in Wistar rats. ( Araújo, CV; Barbosa, AL; Brito, GA; Câmara, CC; Costa, CM; da Silva, AP; Gomes, AS; Oriá, RB; Ramos, HF; Ribeiro, RA; Vale, ML, 2013) |
| "The edema was considered to be caused by pregabalin and the medicine was ceased gradually." | 1.38 | Reversible post-pregabalin peripheral edema in a spinal cord injury patient. ( Duman, I; Guzelkucuk, U; Tan, AK; Yılmaz, B, 2012) |
| "Gabapentin and duloxetine reversed mechanical hyperalgesia but did not normalize gait in any nerve injury model." | 1.35 | Abnormal gait, due to inflammation but not nerve injury, reflects enhanced nociception in preclinical pain models. ( Cummons, TA; Harrison, JE; Leventhal, L; Lu, P; Piesla, MJ; Strassle, BW; Whiteside, GT, 2009) |
| "Both indomethacin and morphine were able to block or reverse thermal hyperalgesia and normalize gait in the CARR model." | 1.35 | Abnormal gait, due to inflammation but not nerve injury, reflects enhanced nociception in preclinical pain models. ( Cummons, TA; Harrison, JE; Leventhal, L; Lu, P; Piesla, MJ; Strassle, BW; Whiteside, GT, 2009) |
| "Gabapentin was effective in the last two attacks." | 1.33 | A case of recurrent and migratory complex regional pain syndrome type I: Prevention by gabapentin. ( Akkus, S; Yener, M; Yorgancigil, H, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (53.85) | 29.6817 |
| 2010's | 10 (38.46) | 24.3611 |
| 2020's | 2 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Martínez, HR | 1 |
| Figueroa-Sanchez, JA | 1 |
| Rodriguez-Gonzalez, I | 1 |
| Rodriguez-Gomez, GP | 1 |
| Ayoub, R | 1 |
| Jarrar, Q | 1 |
| Ali, D | 1 |
| Moshawih, S | 1 |
| Jarrar, Y | 1 |
| Hakim, M | 1 |
| Zakaria, Z | 1 |
| Ho, JM | 1 |
| Tricco, AC | 1 |
| Perrier, L | 1 |
| Chen, M | 1 |
| Juurlink, DN | 1 |
| Straus, SE | 1 |
| Maciel, IS | 1 |
| Silva, RB | 1 |
| Morrone, FB | 1 |
| Calixto, JB | 2 |
| Campos, MM | 1 |
| Câmara, CC | 1 |
| Ramos, HF | 1 |
| da Silva, AP | 1 |
| Araújo, CV | 1 |
| Gomes, AS | 1 |
| Vale, ML | 1 |
| Barbosa, AL | 2 |
| Ribeiro, RA | 1 |
| Brito, GA | 1 |
| Costa, CM | 1 |
| Oriá, RB | 1 |
| Dias, JM | 1 |
| de Brito, TV | 1 |
| de Aguiar Magalhães, D | 1 |
| da Silva Santos, PW | 1 |
| Batista, JA | 1 |
| do Nascimento Dias, EG | 1 |
| de Barros Fernandes, H | 1 |
| Damasceno, SR | 1 |
| Silva, RO | 1 |
| Aragão, KS | 1 |
| Souza, MH | 1 |
| Medeiros, JV | 1 |
| Rytter, S | 1 |
| Stilling, M | 1 |
| Munk, S | 1 |
| Hansen, TB | 1 |
| Wustmann, T | 1 |
| Piro, J | 1 |
| Gutmann, P | 1 |
| Inoue, N | 1 |
| Ito, S | 1 |
| Tajima, K | 1 |
| Nogawa, M | 1 |
| Takahashi, Y | 1 |
| Sasagawa, T | 1 |
| Nakamura, A | 1 |
| Kyoi, T | 1 |
| Piesla, MJ | 1 |
| Leventhal, L | 1 |
| Strassle, BW | 1 |
| Harrison, JE | 1 |
| Cummons, TA | 1 |
| Lu, P | 1 |
| Whiteside, GT | 1 |
| Krüger, S | 1 |
| Lindstaedt, M | 1 |
| Hey, M | 1 |
| Wilson, I | 1 |
| Johnson, MI | 1 |
| Erdoğan, G | 1 |
| Ceyhan, D | 1 |
| Güleç, S | 1 |
| Guzelkucuk, U | 1 |
| Duman, I | 1 |
| Yılmaz, B | 1 |
| Tan, AK | 1 |
| Gallagher, R | 1 |
| Apostle, N | 1 |
| Sharma, HS | 2 |
| Sjöquist, PO | 1 |
| Guéguen, A | 1 |
| Guy, C | 1 |
| Cartry, O | 1 |
| Bouchou, K | 1 |
| Gouilloud, S | 1 |
| Cathébras, P | 1 |
| Dworkin, RH | 1 |
| Corbin, AE | 1 |
| Young, JP | 1 |
| Sharma, U | 1 |
| LaMoreaux, L | 1 |
| Bockbrader, H | 1 |
| Garofalo, EA | 1 |
| Poole, RM | 1 |
| Kassuya, CA | 1 |
| Silvestre, AA | 1 |
| Rehder, VL | 1 |
| Parsons, B | 1 |
| Tive, L | 1 |
| Huang, S | 1 |
| Serena, J | 1 |
| Blanco, M | 1 |
| Castellanos, M | 1 |
| Silva, Y | 1 |
| Vivancos, J | 1 |
| Moro, MA | 1 |
| Leira, R | 1 |
| Lizasoain, I | 1 |
| Castillo, J | 1 |
| Dávalos, A | 1 |
| Akkus, S | 1 |
| Yorgancigil, H | 1 |
| Yener, M | 1 |
| Málaga, I | 1 |
| Sanmarti, FX | 1 |
| Pinto, LG | 1 |
| Jesse, CR | 1 |
| Nogueira, CW | 1 |
| Savegnago, L | 1 |
| Baron, R | 1 |
| Brunnmüller, U | 1 |
| Brasser, M | 1 |
| May, M | 1 |
| Binder, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Preoperative Steroids Injection on Pain and Oedema After Total Knee Arthroplasty . A Double -Blinded Randomized Controlled Study.[NCT04084912] | Phase 3 | 86 participants (Anticipated) | Interventional | 2020-01-01 | Not yet recruiting | ||
| Efficacy of Steroids on Functional Outcomes After Musculoskeletal Injuries of the Hand[NCT05003596] | Phase 2/Phase 3 | 60 participants (Anticipated) | Interventional | 2021-09-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for gamma-aminobutyric acid and Anasarca
| Article | Year |
|---|---|
Risk of heart failure and edema associated with the use of pregabalin: a systematic review.
Topics: Edema; gamma-Aminobutyric Acid; Heart Failure; Humans; Outcome Assessment, Health Care; Pregabalin; | 2013 |
Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia.
Topics: Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Dizziness; Dose-Response Relationship, Drug; | 2004 |
3 trials available for gamma-aminobutyric acid and Anasarca
| Article | Year |
|---|---|
Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial.
Topics: Adult; Affect; Aged; Analgesics, Non-Narcotic; Dizziness; Double-Blind Method; Edema; Female; gamma- | 2003 |
The prediction of malignant cerebral infarction by molecular brain barrier disruption markers.
Topics: Aged; Biomarkers; Blood-Brain Barrier; Brain; Case-Control Studies; Edema; Female; Fibronectins; gam | 2005 |
Efficacy and safety of pregabalin in patients with diabetic peripheral neuropathy or postherpetic neuralgia: Open-label, non-comparative, flexible-dose study.
Topics: Adolescent; Adult; Aged; Anxiety; Diabetic Neuropathies; Dizziness; Dose-Response Relationship, Drug | 2008 |
21 other studies available for gamma-aminobutyric acid and Anasarca
| Article | Year |
|---|---|
Generalized edema with pregabalin in a patient with fibromyalgia.
Topics: Analgesics; Edema; Fibromyalgia; gamma-Aminobutyric Acid; Humans; Pregabalin | 2023 |
Synthesis of Novel Esters of Mefenamic Acid with Pronounced Anti-nociceptive Effects and a Proposed Activity on GABA
Topics: Analgesics; Analgesics, Opioid; Animals; Anti-Inflammatory Agents; Edema; Esters; gamma-Aminobutyric | 2021 |
Synergistic effects of celecoxib and bupropion in a model of chronic inflammation-related depression in mice.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Antidepressive Agents; Behavior, Animal; Brain-Derive | 2013 |
Oral gabapentin treatment accentuates nerve and peripheral inflammatory responses following experimental nerve constriction in Wistar rats.
Topics: Administration, Oral; Amines; Analgesics; Animals; Cell Movement; Constriction, Pathologic; Cyclohex | 2013 |
Gabapentin, a synthetic analogue of gamma aminobutyric acid, reverses systemic acute inflammation and oxidative stress in mice.
Topics: Acute Disease; Amines; Animals; Anti-Inflammatory Agents; Cyclohexanecarboxylic Acids; Edema; Gabape | 2014 |
Methylprednisolone reduces pain and decreases knee swelling in the first 24 h after fast-track unicompartmental knee arthroplasty.
Topics: Acetaminophen; Aged; Aged, 80 and over; Amines; Analgesics; Anti-Inflammatory Agents; Arthroplasty, | 2017 |
Methylprednisolone reduces pain and decreases knee swelling in the first 24 h after fast-track unicompartmental knee arthroplasty.
Topics: Acetaminophen; Aged; Aged, 80 and over; Amines; Analgesics; Anti-Inflammatory Agents; Arthroplasty, | 2017 |
Methylprednisolone reduces pain and decreases knee swelling in the first 24 h after fast-track unicompartmental knee arthroplasty.
Topics: Acetaminophen; Aged; Aged, 80 and over; Amines; Analgesics; Anti-Inflammatory Agents; Arthroplasty, | 2017 |
Methylprednisolone reduces pain and decreases knee swelling in the first 24 h after fast-track unicompartmental knee arthroplasty.
Topics: Acetaminophen; Aged; Aged, 80 and over; Amines; Analgesics; Anti-Inflammatory Agents; Arthroplasty, | 2017 |
Metabolic considerations in a case of pregabalin-induced edema.
Topics: Alcoholism; Anticonvulsants; Edema; Female; gamma-Aminobutyric Acid; Humans; Middle Aged; Pregabalin | 2009 |
Etodolac attenuates mechanical allodynia in a mouse model of neuropathic pain.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Celecoxib; Cyclooxygenase 2 Inhibitor | 2009 |
Abnormal gait, due to inflammation but not nerve injury, reflects enhanced nociception in preclinical pain models.
Topics: Amines; Analgesics, Opioid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Axotomy; Carrageenan; | 2009 |
Pregabalin and edema in young women suffering from premenstrual syndrome.
Topics: Adult; Analgesics; Anxiety Disorders; Edema; Female; gamma-Aminobutyric Acid; Humans; Pregabalin; Pr | 2010 |
Stellate ganglion blockade (SGB) for refractory index finger pain - a case report.
Topics: Abdominal Pain; Accidental Falls; Acetaminophen; Adult; Amines; Autonomic Nerve Block; Chronic Disea | 2011 |
Possible heart failure associated with pregabalin use: case report.
Topics: Amines; Analgesics; Back Pain; Cyclohexanecarboxylic Acids; Diagnosis, Differential; Edema; Female; | 2011 |
Reversible post-pregabalin peripheral edema in a spinal cord injury patient.
Topics: Adult; Analgesics; Edema; gamma-Aminobutyric Acid; Humans; Lower Extremity; Male; Neuralgia; Paraple | 2012 |
Peripheral edema with pregabalin.
Topics: Aged; Analgesics; Diagnosis, Differential; Edema; Female; gamma-Aminobutyric Acid; Humans; Neuralgia | 2013 |
A new antioxidant compound H-290/51 modulates glutamate and GABA immunoreactivity in the rat spinal cord following trauma.
Topics: Animals; Antioxidants; Blood-Brain Barrier; Edema; gamma-Aminobutyric Acid; Glutamic Acid; Male; Neu | 2002 |
[Edematous syndrome and alithiasic cholecystitis induced by gabapentin].
Topics: Acetates; Adult; Amines; Anticonvulsants; Cholecystitis; Cyclohexanecarboxylic Acids; Edema; Epileps | 2002 |
Anti-allodynic and anti-oedematogenic properties of the extract and lignans from Phyllanthus amarus in models of persistent inflammatory and neuropathic pain.
Topics: Acetates; Amines; Analgesics; Animals; Anti-Inflammatory Agents; Cyclohexanecarboxylic Acids; Edema; | 2003 |
A case of recurrent and migratory complex regional pain syndrome type I: Prevention by gabapentin.
Topics: Amines; Cyclohexanecarboxylic Acids; Edema; Foot Diseases; Gabapentin; gamma-Aminobutyric Acid; Huma | 2006 |
Hyperthermia influences excitatory and inhibitory amino acid neurotransmitters in the central nervous system. An experimental study in the rat using behavioural, biochemical, pharmacological, and morphological approaches.
Topics: Animals; Aspartic Acid; Behavior, Animal; Blood-Brain Barrier; Brain; Capillary Permeability; Cerebr | 2006 |
Two cases of painful gynecomastia and lower extremity pain in association with pregabalin therapy.
Topics: Adolescent; Anticonvulsants; Edema; Epilepsy; gamma-Aminobutyric Acid; Gynecomastia; Humans; Ilium; | 2006 |
Evidence for the involvement of glutamatergic and GABAergic systems and protein kinase A pathway in the antinociceptive effect caused by p-methoxy-diphenyl diselenide in mice.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Acetic Acid; Analgesics; Animals; Benzene Derivatives; Capsa | 2008 |